Objectives: Left ventricular ejection fraction (EF) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are important surrogate markers of cardiac function and wall stress. Randomized trials of heart failure (HF) have shown improvements in survival in patients with reduced EF (50%) was rare (14.1% of patients with HFrEF and 26.7% with HFmrEF), some degree of improvement was observed in 57.7% and 46.7% of patients. LVEF improved on average 9.1% in patients with HFrEF (p < .001) and NT-proBNP decreased from 4,202 to 2,030 pg/ml (p < .001). A similar trend was noticed for the HFmrEF group but was not statistically significant. The improvement in LVEF was consistent across subgroups with HF attributable to IHD (6.2%), idiopathic dilated c...
AbstractHeart failure (HF) biomarkers have dramatically impacted the way HF patients are evaluated a...
Objective: The importance of the NT-proBNP value in detecting patients at risk of developing heart f...
Background: N-terminal pro–B-type natriuretic peptide (NT-proBNP) is used for diagnostic and prognos...
Objectives: Left ventricular ejection fraction (EF) and N-terminal pro-B-type natriuretic peptide (N...
ObjectivesThis study sought to determine the prognostic value of B-type natriuretic peptide (BNP) in...
Aims The proportion of patients hospitalized for heart failure (HF) with preserved left ventricular ...
Between 2013 and 2016 there were approximately 6.2 million adults in the United States living with h...
Aim: The prognostic value of natriuretic peptides in the management of heart failure (HF) patients w...
Aims The study aimed at investigating the use of guideline-recommended diagnostic tools and medicati...
Aim: Recent data suggest that guideline-directed medical therapy of patients with heart failure (HF)...
AIMS: While heart failure with preserved (HFpEF) and reduced ejection fraction (HFrEF) are well desc...
BACKGROUND: Effective therapies for HFrEF usually reduce NT-proBNP (N-terminal pro-B-type natriureti...
Heart failure (HF) is a growing challenge in the Asia Pacific region. N-terminal pro-B-type natriure...
AbstractHeart failure (HF) biomarkers have dramatically impacted the way HF patients are evaluated a...
Objective: The importance of the NT-proBNP value in detecting patients at risk of developing heart f...
Background: N-terminal pro–B-type natriuretic peptide (NT-proBNP) is used for diagnostic and prognos...
Objectives: Left ventricular ejection fraction (EF) and N-terminal pro-B-type natriuretic peptide (N...
ObjectivesThis study sought to determine the prognostic value of B-type natriuretic peptide (BNP) in...
Aims The proportion of patients hospitalized for heart failure (HF) with preserved left ventricular ...
Between 2013 and 2016 there were approximately 6.2 million adults in the United States living with h...
Aim: The prognostic value of natriuretic peptides in the management of heart failure (HF) patients w...
Aims The study aimed at investigating the use of guideline-recommended diagnostic tools and medicati...
Aim: Recent data suggest that guideline-directed medical therapy of patients with heart failure (HF)...
AIMS: While heart failure with preserved (HFpEF) and reduced ejection fraction (HFrEF) are well desc...
BACKGROUND: Effective therapies for HFrEF usually reduce NT-proBNP (N-terminal pro-B-type natriureti...
Heart failure (HF) is a growing challenge in the Asia Pacific region. N-terminal pro-B-type natriure...
AbstractHeart failure (HF) biomarkers have dramatically impacted the way HF patients are evaluated a...
Objective: The importance of the NT-proBNP value in detecting patients at risk of developing heart f...
Background: N-terminal pro–B-type natriuretic peptide (NT-proBNP) is used for diagnostic and prognos...